Solid biosciences reports third quarter 2024 financial results and provides business updates

- duchenne: dosing completed for first three patients in inspire duchenne clinical trial; sgt-003 has been well tolerated in all patients with no saes observed; initial three patient data expected q1 2025 -

SLDB Ratings Summary

SLDB Quant Ranking